Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 30, Issue 5-6, 1998, Pages 525-538

  Schnell, R ^a   Vitetta, E ^b,d   Schindler, J ^b,d   Barth, S ^a   Winkler, U ^a   Borchmann, P ^a   Hansmann, M L ^c   Diehl, V ^a   Ghetie, V ^b,d   Engert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Univ of Texas SW Medical School   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

CD25; Hodgkin's lymphoma; Immunotoxin; RFT5 SMPT dgA

Indexed keywords

CD30 ANTIGEN; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; RICIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TACHYCARDIA; TIME; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 7344268577     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057565     Document Type: Article

References (53)

1. De Vita, V. T. and Molloy Hubbard S. Hodgkin's lymphoma (1983). New Engl. J. Med., 328, 560-565.
2. Longo, I. L., Young, R. C. and Wesley, M. (1986). Twenty years of MOPP therapy for Hodgkin's lymphoma, J. Clin. Oncol., 4, 1295-1306.
3. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, R. and the German Cancer Aid 17-1A Study Group (1994). Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet, 343, 1177-1183.
4. Ro, D. C., Griffin, J. D., Belvin, M., Blättler, W. A., Lambert, J. M. and Ritz, J. (1991). Anti-My9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood, 77, 2404-2412.
5. Gribben, J. G., Freedman, A. S., Neuberg, D., Roy, D. C., Blake, K. W., Woo, S. D., Grossbard, M. L., Rabinowe, S. N., Coral, F., Freeman, G. J., Riyz, J. and Nadler, L. M. (1991). Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med., 325, 1525-1533.
6. Simonsson, B. (1996). Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options. Leukemia, 10 Suppl 2, 44-45.
7. Mitchell, M. S. (1995). Active specific immunotherapy of melanoma.Br. Med. Bull., 51 (3), 631-645.
8. Grossbard, M. L., Gribben, J. G., Freedman, A. S., Lambert, J., Kinsella, J., Rabinowe, S., Eliseo, L., Taylor, J., Blatter, W., Epstein, C. and Nadler, L. (1993). Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood, 81, 2263-2271.
9. Schnell, R., Barth, S., Diehl, V. and Engert, A. (1996). Hodgkin's disease. Future treatment strategies: fact or fiction. In Baillieres Clinical Haematology, V. Diehl (ed.), pp.573-593.
10. Hsu, S. M. and Jaffe, E. S. (1984). Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's lymphoma. Am. J. Clin. Pathol., 82, 29-32.
11. Hsu, S. M., Ho, Y. S. and Hsu, P. L. (1987). Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells. J. Nat. Cancer Inst., 79, 1091-1097.
12. Stein, H., Mason, D. Y., Gerdes, J., O'Conner, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H., Schwarting, R. and Lennert, K. (1985). The expression of the Hodgkin's-disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Sternberg-Reed cells and histocytic malignancies are derived from activated lymphoid cells. Blood, 66, 848-858.
13. Agnarsson, B. A. and Kadin, M. E. (1989). The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's lymphoma using fixed frozen tissue. Cancer, 63, 2083-2087.
14. Casey, T. T., Olson, S. J., Cousar, J. B. and Collins, R. D. (1989). Immunophenotypes of Reed-Sternberg cells: a study of 19 cases of Hodgkin's lymphoma in plastic-embedded sections. Blood, 74, 5042-5046.
15. Kennedy, I. C., Hart, D. N. and Colls, B. M. (1989). Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's lymphoma are probable dendritic cell malignancies. Clin. Exp. Immunol., 76, 324-331.
16. Delabie, J., Ceuppens, J. L., Vandenberghe, P., de Boer, M., Coorevits, L. and de Wolf-Peeters, C. (1993). The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's lymphoma and contributes to the stimulating capacity of Hodgkin's lymphoma-derived cell lines. Blood, 82, 2845-2852.
17. Taniguchi, T. and Minami, Y. (1993). The IL-2/IL-2 receptor system: a current overview. Cell, 73, 5-8.
18. Kreitman, R. J. and Pastan, I. (1994). Recombinant single-chain immunotoxins against T- and B-cell leukemias. Leuk. Lymph., 13, 1-10.
19. Strauchen, J. A. and Breakstone, B. A. (1987). IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am. J. Pathol., 126, 506-512.
20. Till, M., May, R. D., Uhr, J. W., Thorpe, P. E. and Vitetta, E. S. (1988). An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins Cancer Res., 48, 1119-1123.
21. Diehl, V., Kirchner, H. H., Schaadt, M., Fonatsch, C., Stein, H., Gerdes, J. and Boie, C. (1981 ). Hodgkin's disease: establishment and characterization of four in vitro cell lines. J. Cancer Res. Clin. Oncol., 101, 111-124.
22. Casellas, P., Brown, J. P., Gros, O., Gros, P., Hellstrom, I., Jansen, F. K., Poncelet, P., Roncucci, R., Vidal, H. and Hellstrom, K. E. (1981). Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int. J. Cancer, 30, 437-443.
23. Engert, A., Martin, G., Amlot, P., Wijdenes, J., Diehl, V. and Thorpe, P. (1991). Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int. J. Cancer, 49, 450-456.
24. Winkler, U., Gottstein, C., Schön.,G., Kapp, U., Wolf, J., Hansmann, M. L., Bohlen, H., Thorpe, P., Diehl, V. and Engert, A. (1994). Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins Blood, 83, 466-475.
25. Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, M. T., Drillich, S., Schön, G., Bohlen, H., Tesch, H., Hansmann, M. L., Barth, S., Schindler, J., Ghetie, V., Uhr, J. and Vitetta, E. (1997). A Phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89 (2), 403-410.
26. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. and Thorpe, P. (1991). Phase-I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51, 4052-4058.
27. Amlot, P., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramillo, O., Thorpe, P., Uhr, J. and Vitetta, E. S. (1993). A Phase-I study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82, 2624-2633.
28. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Schindler, J., Uhr, J. W., Wittes, R. E. and Vitetta, E. S. (1995). Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A Phase-I study. Blood, 85, 3457-3465.
29. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R.H., Figg, W.D., Stetler-Stevenson, M., Jain, V., Jaffe, E.S., Solomon, D., Lush, R. M., Senderowilz, A., Ghetic, V., Schindler, J., Uhr, J. W. and Vitetta, E. S. (1996). A Phase-I study of bolus vs. continuous infusion of the anti-CD 19 immunotoxin, IgG-HL37-dgA in patients with B cell lymphoma. Blood, 88 (4), 1188-1197.
30. Vitetta, E. S., Thorpe, P. E. and Uhr, J. W. (1993). Immunotoxins: magic bullets or misguided missiles? Immunol. Today, 14, 252-259.
31. Byers, V. S. and Baldwin, R. W. (1991). Rationale for clinical use of immunotoxins in cancer and autoimmune diseases. Sem. Cell Biol., 2, 59-70.
32. Durrant, L. G., Byers, V. S., Scannon, P. J., Rodvien, R., Grant, K., Robins, R. A., Marksman, R. A., and Baldwin, R. W. (1989). Humoral immune resonses to XMMCO-791-RTA immunotoxins in colorectal cancer patients. Clin. Exp. Immunol., 75, 258-264.
33. Junghans, R. P. and Waldmann, T. A. (1996). Metabolism of TAC (IL2Rα): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J. Exp. Med., 185, 1587-1602.
34. Kreitman, R. J., Chaudhary, V. K., Kozak, R. W., FitzGerald, D. J. P., Waldmann, T. A. and Pastan, I. (1992). Recombinant toxins containing the variable domains of the anti-TAC monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood, 80, 2344-2352.
35. Kreitman, R. J., Chaudhary, V. K., Waldmann, T. A., Hanchard, B., Cranston, B., FitzGerald, D. J. P. and Pastan, I. (1993). Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or Diphteria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia, 7, 553-562.
36. 486IL-2 in advanced mycosis fungoides and the Sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a Phase-II study. Blood, 84, 1765-1774.
37. Foss, F. M., Nichols, J., Parker, K. and the Seragen Lymphoma Study Group. Phase-I/II trial of DAB389IL-2 in patients with NHL, HL and CTCL. (1995). Fourth International Symposium on Immunotoxins 159A.
38. Williams, D. P., Parker, K., Bacha, P., Bishai. W., Borowksi, M., Genbauffe, F., Strom, T. B. and Murphy, J. R. (1987). Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Prot Eng, 1. 493-498.
39. LeMaistre, C. F., Craig, F. E., Meneghetti, C. M., McMullin, B., Parker, K., Reuben, J., Boldt, D. H., Rosenblum, M. and Woodworth, T. (1993). Phase-I trial of a 90-minute infusion of the fusion toxin DAB4861L-2 in hematological cancers Cancer Res, 53, 3930-3934.
40. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 79, 2547-2554.
41. 486,IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer, 73, 1276-1285.
42. Schwab, U., Stein, H., Gerdes, J., Kirchner, H., Schaadt, M. and Diehl, V. (1982). Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's lymphoma and a subset of normal lymphoid cells. Nature, 299, 65-67.
43. + lymphoma: in vitro evaluation. Br. J. Haematol., 81, 203-211.
44. + anaplastic large-cell lymphoma. Blood, 85, 2139-2146.
45. Falini, B., Bolognesi, A., Flenghi, L., Tazzari, P. L., Broe, M. K., Stein, H. and Dürkop, H. (1992). Response of refractory Hodgkin's lymphoma to monoclonal anti-CD30 immunotoxin. Lancet, 339, 1195-1196.
46. Falini, B., Pasqualucci, L., Flenghi, L., Bolognesi, A., Kadin, M., Stein, H., Martinelli, M. F. and Stirpe, F. Anti-CD30 immunotoxins: experimental and clinical studies. Abstracts of the Fourth International Symposium on Immunotoxins 1995, 160.
47. Engert, A., Burrows, F., Jung, W., Tazzari, P. L., Stein, H., Pfreundschuh, M., Diehl, V. and Thorpe, P. (1990). Evaluation of ricin A-chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's lymphoma. Cancer Res., 50, 84-88.
48. Engert, A., Martin, G., Pfreundschuh, M., Amlot, P., Hsu, S. M., Diehl, V. and Thorpe, P. E. (1990). Antitumor effects of ricin A-chain immunotoxins prepared from intact antibodies and Fab′ fragments on solid human Hodgkin's lymphoma tumors in mice. Cancer Res., 50, 2929-2935.
49. Horn-Lohrens, O., Tiemann, M., Lange, H., Koharg, J., Hafner, M., Hansen, H., Sterry, W., Parwaresch, R. M. and Lemke, H. (1995). Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). In. J. Cancer, 60, 539-544.
50. Schnell, R., Linnartz, C., Schön, G., Katouzi, A., Bohlen, H., Horn-Lohrens, O., Parwaresch, R., Diehl, V., Lemke, H. and Engert, A. (1995). Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int. J. Cancer, 63, 238-244.
51. Engert, A., Gottstein, C., Bohlen, H., Winkler, U., Schön. G., Manske, O., Schnell, R., Diehl, V. and Thorpe, P. (1995). Cocktails of ricin A-chain immunotoxins against different antigens of Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int. J. Cancer, 63, 304-309.
52. Katz, F. E., Janossy, G., Cumber, A., Ross, W., Blacklock, H. A., Tax, W. and Thorpe, P. E. (1987). Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Brit. J. Haemalot., 67, 407-411.
53. Ghetie, M. A., Tucker, K., Richardson, J., Uhr, J. W. and Vitetta, E. S. (1992). The antitumor activity of an anti-CD 22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD 19 antibody or an anti-CD 19 immunotoxin. Blood, 80, 2315-2320.